- Novartis will expand its North Carolina operations through a new flagship manufacturing hub covering biologics, sterile packaging and solid dosage production.
- The expansion is part of a $23 billion investment to enable end-to-end manufacturing of all key Novartis medicines in the United States over the next five years.
Novartis has announced plans to expand its operations in North Carolina with the creation of a new flagship manufacturing hub. The investment forms part of the company’s five-year, $23 billion commitment to build end-to-end manufacturing capacity for its key medicines in the United States.
The expansion includes two new facilities in Durham dedicated to biologics manufacturing and sterile packaging, and a new site in Morrisville for producing solid dosage tablets and capsules. Novartis will also increase the scope of its existing Durham facility by adding sterile filling capability for biologics.
The company said the wider programme will bring all advanced technologies under US production, including cell and gene therapies manufactured in New Jersey and North Carolina, radioligand therapies produced across multiple states, and xRNA therapies to be manufactured at a future US site. The consolidated North Carolina hub will support medicines across oncology, immunology, neuroscience and cardiovascular, renal and metabolic therapy areas.
“This announcement is a commitment to American innovation and to the patients we serve,” said Vas Narasimhan, CEO of Novartis. He stated that the expansion will strengthen supply chain resilience and support delivery of new medicines. North Carolina Governor Josh Stein said the investment reflects the state’s strengths in advanced pharmaceutical manufacturing.
The new and expanded facilities, expected to open between 2027 and 2028, will encompass more than 700,000 square feet and create 700 new jobs, with an estimated 3,000 indirect jobs across the supply chain by 2030.
